Navigation Links
Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
Date:9/18/2012

BLUE BELL, Pa., Sept. 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today  that J. Joseph Kim, Ph.D., President and CEO, will present and participate in a panel at BIOX, Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September 24-25, 2012.

Inovio Presentation
Monday, September 24
3:00 PM ET

Panel Presentation
Monday, September 24
5:55 PM ET
"Innovation in Immunotherapy & Vaccines"

Following the event, a high-definition video webcast of the presentation will be available on Inovio's website. It will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast will be archived on Inovio's website for 90 days following the event.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-loo
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
4. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
5. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
6. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
7. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
8. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
9. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... San Francisco, CA (PRWEB) February 27, 2015 ... is joining forces on February 28 with patients and ... to raise awareness for Rare Disease Day®. Rare ... rare diseases and calling attention to the special challenges ... community around them. , “Cytokinetics is proud to stand ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... , ATLANTA, Oct. 27 Craneware ... improvement solutions for U.S. healthcare, today announced a presentation ... Strategies Conference scheduled for November 5-7 in Chicago, IL. ... with more than 30 years experience - Director of ...
... Md., Oct. 27 Precision Antibody(TM) has ... of the National Cancer Institute (NCI),s Clinical Proteomic Technologies ... number and standardizing the quality of monoclonal antibody reagents ... is the result of a third solicitation for contract ...
... Switzerland, Oct. 27 Syngenta Ventures announced today that ... privately-held U.S. biotechnology company focused on the use of ... direct investment by Syngenta Ventures, Syngenta,s newly-established corporate venture ... complement our in-house R&D work and enables us to ...
Cached Biology Technology:Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 2Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 3Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3Syngenta Ventures Invests in U.S. Biotech Company Metabolon 2Syngenta Ventures Invests in U.S. Biotech Company Metabolon 3
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... that could offer a new pathway to restoring vision ... cells in the eye to be light sensitive that ... a gene for a light-sensitive protein into "inner retinal ... that resembles the defect in such inherited human disorders ...
... new 60 and 60 is the new 50, unfortunately for ... it simply isn't true. , New research however from The ... non-pharmaceutical means to maintain muscle function and quality of life ... be as simple as taking a stroll followed by a ...
... Institute, a private laboratory affiliated with the University of Wisconsin-Madison, ... of animal cells and used it to derived two new ... is reported today (Jan. 1, 2006) in the journal Nature ... clinical reality by completely ridding the culture medium in which ...
Cached Biology News:'Prosthetic' retinal cells let blind mice see light 2Chocolate milk could be key to longer, healthier life 2Wisconsin scientists grow two new stem cell lines in animal cell-free culture 2Wisconsin scientists grow two new stem cell lines in animal cell-free culture 3
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... wide variety of solvent vapors that can contaminate and ... allows for the collection of liquid into a self ... waiting period., Ultra low -104 o C ... , Digital Display of temperature ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: